Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

Inclusion criteria:

• Age >18 years old (Adult, Older Adult)

• Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamouscarcinoma of the cervix, FIGO stage IIIB-IVA

• Undergoing for standard of care palliative radiotherapy without chemotherapy as perthe local treatment guideline

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2

• Adequate liver function (aspartate aminotransferase (AST) and alanineaminotransferase (ALT) ≤2.5 x ULN (Upper Limit of Normal); total serum bilirubin ≤1.5 x ULN); blood cell counts (absolute neutrophils count ≥1.500/mm3; plateletcount ≥100.000/mm3; hemoglobin ≥10.0 g/dL); renal function (serum creatinine ≤1.5 xULN; estimate creatinine clearance (Cockcroft-Gault) ≥60 mL/min)

• Participants must have measureable disease according to the Response EvaluationCriteria in Solid Tumors (RECIST) V1.1.

• Agree to use an effective form of contraception (e.g., true abstinence (not periodicabstinence), barrier contraception, highly effective hormonal contraception) if theparticipant is of child bearing age

• Give informed consent

Exclusion criteria:

• Cervical cancer patients who are candidates for single dose palliative radiotherapy

• Patients with severe or bilateral hydronephrosis

• Evidence of distant metastases

• Receiving any other investigational agent concurrently or within the last 4 weeksbefore enrollment

• Received any previous radiation or chemotherapy for cervical cancer

• Underwent surgery in the four weeks prior to the enrolment date or scheduled toundergo surgery within eight weeks after end of treatment

• Currently using of any chemotherapy or scheduled to receive within eight weeks afterend of treatment

• Known allergy to turmeric or its derivatives (ginger, curry, cumin, or cardamom)

• Known allergy to fenugreek, peanut, soy, lentil, pea, bean, and chickpea

• Presence of conditions that precludes the safe administration of the trialintervention and/or prohibit adequate compliance to study requirements includingchronic ongoing infections (like HIV, Hepatitis B or C), uncontrolled hypertension,heart failure, cardiac arrhythmia, unstable angina, chronic obstructive lungdisease, diabetes mellitus, chronic renal disease, chronic liver disease, biliarytract obstruction or cholelithiasis, gastric or duodenal ulcers, autoimmune orinflammatory disorders, a coagulation or platelet disorder, seizure disorders andpsychiatric illness. Patients with disorders other than the ones specified above mayalso be excluded based on the judgment of the principal investigator.

• Pregnant and breastfeeding women

• Participants with circumstances that will not permit completion of the study orrequired follow-up. For instance, if travel to and from treatment site is an issue.